REGN

+ Watchlist + Portfolio

Regeneron Pharmaceuticals, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $840.84
52-Week Range: $541.00 – $844.92
Market Cap: $85.11B
P/E (TTM): 20.44
EPS (TTM): 40.44
Dividend Yield: 0.45%

Advanced Metrics

Price/Book: 2.62
PEG Ratio: 1.39
Return on Equity: 14.04%
Return on Assets: 6.53%
Gross Margin: 44.46%
Operating Margin: 33.11%
Profit Margin: 27.87%
Current Ratio: 3.33
Debt/Equity: 0.09
Total Debt: $2.71B
Free Cash Flow: $3.07B
Revenue Growth: 16.70%
Earnings Growth: -4.50%
Enterprise Value: $78.67B

REGN Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$12.17B	$13.12B	$14.20B	$14.34B
Cost of Revenue	$1.56B	$1.82B	$1.97B	$2.10B
Gross Profit	$10.61B	$11.30B	$12.23B	$12.24B
Research & Development	$3.85B	$4.63B	$5.23B	$5.85B
Selling, General & Admin	$2.12B	$2.63B	$2.95B	$2.70B
Operating Expenses	$5.87B	$7.25B	$8.24B	$8.54B
Operating Income	$4.74B	$4.05B	$3.99B	$3.70B
EBITDA	$5.26B	$4.69B	$5.32B	$5.82B
Pretax Income	$4.86B	$4.20B	$4.78B	$5.23B
Income Tax	$520.40M	$245.70M	$367.30M	$725.80M
Net Income	$4.34B	$3.95B	$4.41B	$4.50B
Diluted EPS	38.22	34.77	38.34	41.48
Diluted Shares	113.50M	113.70M	115.10M	108.60M

REGN Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$3.11B	$2.73B	$2.49B	$3.12B
Receivables	$5.33B	$5.67B	$6.21B	$5.74B
Inventory	$2.40B	$2.58B	$3.09B	$3.20B
Current Assets	$15.88B	$19.48B	$18.66B	$18.02B
Total Assets	$29.21B	$33.08B	$37.76B	$40.56B
Current Liabilities	$3.14B	$3.42B	$3.94B	$4.37B
Long-Term Debt	$1.98B	$1.98B	$1.98B	$1.99B
Total Debt	$2.70B	$2.70B	$2.70B	$2.71B
Total Liabilities	$6.55B	$7.11B	$8.41B	$9.30B
Retained Earnings	$23.31B	$27.26B	$31.67B	$35.80B
Shareholders' Equity	$22.66B	$25.97B	$29.35B	$31.26B
Working Capital	$12.74B	$16.06B	$14.72B	$13.65B

REGN Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$5.01B	$4.59B	$4.42B	$4.98B
Capital Expenditure	-$1.62B	-$926.40M	-$881.60M	-$1.21B
Free Cash Flow	$3.40B	$3.67B	$3.54B	$3.77B
Depreciation & Amortisation	$341.40M	$421.00M	$482.90M	$543.70M
Stock-Based Compensation	$725.00M	$885.00M	$982.80M	$993.70M
Investing Cash Flow	-$3.78B	-$3.19B	-$2.47B	-$629.10M
Financing Cash Flow	-$1.01B	-$1.79B	-$2.20B	-$3.72B
Dividends Paid	—	$0.00	$0.00	-$370.30M
Share Repurchases	-$2.53B	-$2.94B	-$3.63B	-$3.97B
Net Change in Cash	$221.30M	-$381.20M	-$248.10M	$634.40M

REGN Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$3.68B	$3.75B	$3.88B	$3.61B	$4.29B
Cost of Revenue	$530.20M	$521.60M	$584.60M	$669.40M	$576.50M
Gross Profit	$3.15B	$3.23B	$3.30B	$2.94B	$3.71B
Research & Development	$1.43B	$1.48B	$1.63B	$1.54B	$1.63B
Selling, General & Admin	$634.20M	$657.80M	$775.00M	$647.70M	$662.10M
Operating Expenses	$2.07B	$2.12B	$2.40B	$2.19B	$2.29B
Operating Income	$1.08B	$1.11B	$898.60M	$744.80M	$1.42B
EBITDA	$1.66B	$1.92B	$1.20B	$967.30M	$1.66B
Pretax Income	$1.52B	$1.76B	$1.04B	$831.20M	$1.53B
Income Tax	$127.10M	$303.30M	$199.10M	$104.00M	$230.90M
Net Income	$1.39B	$1.46B	$844.60M	$727.20M	$1.30B
Diluted EPS	12.81	13.62	7.86	6.75	12.23
Diluted Shares	108.60M	107.20M	107.50M	107.70M	106.00M

REGN Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$2.00B	$2.51B	$3.12B	$2.96B	$2.46B
Receivables	$5.61B	$5.69B	$5.74B	$5.73B	$6.57B
Inventory	$3.21B	$3.25B	$3.20B	$3.10B	$3.08B
Current Assets	$16.86B	$17.98B	$18.02B	$18.21B	$18.45B
Total Assets	$38.22B	$40.17B	$40.56B	$40.87B	$41.73B
Current Liabilities	$3.67B	$4.43B	$4.37B	$5.11B	$5.53B
Long-Term Debt	$1.99B	$1.99B	$1.99B	$1.99B	$1.99B
Total Debt	$2.71B	$2.71B	$2.71B	$2.71B	$2.71B
Total Liabilities	$8.28B	$9.21B	$9.30B	$9.45B	$10.02B
Retained Earnings	$33.68B	$35.05B	$35.80B	$36.42B	$37.62B
Shareholders' Equity	$29.94B	$30.96B	$31.26B	$31.42B	$31.71B
Working Capital	$13.19B	$13.56B	$13.65B	$13.10B	$12.92B

REGN Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$1.14B	$1.62B	$1.17B	$1.08B	$813.00M
Capital Expenditure	-$406.80M	-$244.70M	-$290.70M	-$279.50M	-$291.20M
Free Cash Flow	$737.60M	$1.37B	$880.00M	$799.40M	$521.80M
Depreciation & Amortisation	$135.10M	$136.70M	$145.00M	$123.20M	$123.70M
Stock-Based Compensation	$251.70M	$237.00M	$249.30M	$257.40M	$243.00M
Investing Cash Flow	-$1.09B	-$402.90M	$220.30M	-$428.90M	-$92.70M
Financing Cash Flow	-$1.13B	-$717.90M	-$780.10M	-$802.20M	-$1.22B
Dividends Paid	-$92.60M	-$91.20M	-$92.70M	-$97.80M	-$96.80M
Share Repurchases	-$1.07B	-$667.00M	-$1.19B	-$867.50M	-$1.18B
Net Change in Cash	-$1.08B	$497.90M	$610.90M	-$152.20M	-$504.30M

Market Snapshot

About

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, and commercializes medicines for serious diseases. Its marketed products include Eylea for retinal diseases, Dupixent for atopic dermatitis and asthma, Libtayo for skin cancer, and Praluent for cholesterol management, developed using its proprietary VelocImmune antibody technology.